Physician profile
Walter Gaman
NPI 1780650291
$5,987.33
in general payments reported to CMS, 2019-2025
49 companies · $68.94 in 2025
The $68.94 reported for 2025 was less than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,789 · 2020: $969 · 2021: $1,825 · 2022: $1,306 · 2023: $16.54 · 2024: $13.23 · 2025: $68.94.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $98.71.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $98.71 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $678.66 | 2019-2022 | |
| Abbvie INC. | $578.16 | 2019-2022 | |
| Novo Nordisk INC | $495.36 | 2019-2024 | Rybelsus, Ozempic |
| Lilly USA, LLC | $456.22 | 2019-2022 | |
| Glaxosmithkline, LLC. | $452.63 | 2019-2022 | |
| Pfizer INC. | $367.75 | 2019-2022 | |
| Amgen INC. | $307.96 | 2019-2022 | |
| Amarin Pharma, INC. | $264.66 | 2019-2022 | |
| Merck Sharp & Dohme LLC | $252.34 | 2019-2022 | |
| Allergan, INC. | $206.71 | 2019-2020 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $189.39 | 2020-2022 | |
| Janssen Biotech, INC. | $127.58 | 2019-2022 | |
| Abbott Laboratories | $103.91 | 2021-2022 | |
| Biohaven Pharmaceutical Holding Company LTD. | $93.51 | 2022 | |
| Cleerly, INC. | $85.48 | 2023-2025 | Cleerly Ischemia, Cleerly Labs |
Show all 49 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Walter Gaman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.